$tr2['classname']

肺癌

$tr2['classname']

乳腺癌

$tr2['classname']

结直肠癌

$tr2['classname']

前列腺癌

$tr2['classname']

甲状腺癌

$tr2['classname']

宫颈癌

$tr2['classname']

胃癌

$tr2['classname']

肝癌

$tr2['classname']

胆囊癌

$tr2['classname']

卵巢癌

$tr2['classname']

食管癌

$tr2['classname']

胰腺癌

$tr2['classname']

膀胱癌

$tr2['classname']

淋巴瘤

$tr2['classname']

子宫内膜癌

$tr2['classname']

肾癌

$tr2['classname']

罕见肿瘤

首页 > TAG信息列表 > KEYNOTE-581

仑伐替尼|上市信息

欧盟委员会批准乐卫玛（仑伐替尼）和可瑞达（帕博利珠单抗）联合用药用于
FDA批准乐卫玛（仑伐替尼）联合可瑞达（帕博利珠单抗）用于一线治疗晚期

仑伐替尼|最新研究

乐卫玛（仑伐替尼）与可瑞达（帕博利珠单抗）联合用药在日本获批用于治疗